Cat. No.: HY-B1811

Vasopressin

(Synonyms: Arginine vasopressin; Antidiuretic hormone)

7 Cited Publications

Customer Review

Based on 7 publication(s) in Google Scholar

Vasopressin is a cyclic nonapeptide that is synthesized centrally in the hypothalamus. Vasopressin participates in the hypothalamic-pituitary-adrenal axis, and regulates pituitary corticotropin secretion by potentiating the stimulatory effects of corticotropin releasing factor. Vasopressin also can act as a neurotransmitter, exerting its action by binding to specific G protein-coupled receptors.

For research use only. We do not sell to patients.

Purity: 99.65%
CAS No.: 11000-17-2
Formula: C₄₆H₆₅N₁₅O₁₂S₂
Molecular Weight:1084.23

Storage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Vasopressin Chemical Structure

CAS No.: 11000-17-2

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (7)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

IC₅₀ & Target

Human Endogenous Metabolite

All Endogenous Metabolite Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A7R5	IC₅₀	10 nM Compound: vasopressin, VS2	Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells Tested for the TYR(Me)2 arginine-vasopressin as radioligand at 0.3 nM in A7r5 cells	10.1016/S0960-894X(97)00050-4
CHO	EC₅₀	2 nM Compound: AVP	Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human vasopressin V1b receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO	EC₅₀	8.3 nM Compound: AVP	Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay Agonist activity at human oxytocin receptor expressed CHO cells assessed as induction of phospholipase C activity after 15 mins by inositol phosphate accumulation assay	[PMID: 21428295]
CHO-K1	EC₅₀	15 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay Agonist activity at human OT receptor expressed in CHO-K1 cells by luciferase reporter gene assay	[PMID: 21688787]
CHO-K1	EC₅₀	22 nM Compound: AVP	Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human oxytocin receptor expressed in CHO-K1 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
COS-1	EC₅₀	41 nM Compound: 2, AVP	Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay Activity at oxytocin receptor expressed in COS1 cells assessed as IP-one generation by HTRF assay	[PMID: 21117646]
Flp-In-293	EC₅₀	4.3 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V1b receptor expressed in Flp-In-293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.0035 nM Compound: AVP	Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1b receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.004 nM Compound: AVP	Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human V1a receptor expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.05 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V2 receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.05 nM Compound: AVP	Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V2 expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	0.07 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant rat vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.1 nM Compound: AVP	Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method Agonist activity at recombinant human OTR expressed in HEK293 cells assessed as increase in intracellular calcium level measured at 3 secs interval for 5 mins by fura-2/AM dye based micro spectrofluorometric method	[PMID: 30896946]
HEK293	EC₅₀	0.24 nM Compound: 1, AVP, [Arg8]vasopressin	Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay Agonist activity at recombinant human vasopressin V1a receptor expressed in HEK293 cells by luciferase reporter gene assay	[PMID: 21688787]
HEK293	EC₅₀	0.24 nM Compound: AVP	Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1a expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]
HEK293	EC₅₀	4.3 nM Compound: AVP	Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay Agonist activity at human vasopressin V1b expressed in HEK293 cells after 5 hrs by firefly luciferase reporter gene assay	[PMID: 24874785]

In Vitro

AVP (0.01 nM-1 μM) induces Ca²⁺ increase in Chinese hamster ovary cells expressing rat or human V_1b receptors^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Vasopressin (0.03-0.3 μg/kg; i.p.) potentiates corticotropin release provoked by exogenous corticoliberin and increases corticotropin secretion subsequent to body water loss^[2].
Vasopressin (0.001-0.1 mg/kg; i.p.) potently increases adjacent lying, where rats meeting for the first time lie passively next to each other^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 11000-17-2
Appearance Solid
Molecular Weight 1084.23
Formula C₄₆H₆₅N₁₅O₁₂S₂
Color White to off-white
Synonyms

Arginine vasopressin; Antidiuretic hormone
Sequence

Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bridge: Cys1-Cys6)
Sequence Shortening

CYFQNCPRG-NH2 (Disulfide bridge: Cys1-Cys6)
Structure Classification
- Cyclopeptides
Initial Source
- Endogenous metabolite
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (7)

All Cell Imaging/StainingRT-PCRBio/Physico-chemical AssayWB

Sort by:

Journal Impact Factor

Nat Commun

Structural insights into antagonist recognition by the vasopressin V2 receptor. [Abstract]

2025 Nov 4;16(1):9734. PMID: 41188237
Nat Commun

Oxytocinergic input from the paraventricular nucleus to the nucleus accumbens core modulates methamphetamine-conditioned place preference. [Abstract]

2025 May 23;16(1):4808. PMID: 40410135
Eur J Pharmacol

Melatonin activates the Mst1-Nrf2 signaling to alleviate cardiac hypertrophy in pulmonary arterial hypertension. [Abstract]

2022 Oct 15:933:175262. PMID: 36100129

Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]

Vasopressin (AVP) (10 μM; 48 h) increased neonatal primary rat cardiomyocyte surface areas.

Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]

Vasopressin (AVP) (10 μM; 48 h) increased mRNA expression levels of cardiomyocyte hypertrophy markers BNP, TRPC6, and β-MHC in cardiomyocytes.

Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]

Vasopressin (AVP) (10 μM; 48 h) markedly increased malondialdehyde (MDA) levels, an indicator of mitochondrial oxidative stress levels, in cardiomyocytes.

Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]

Representative fluorescent JC-1 images and quantification of mitochondrial membrane potential (MMP) levels, in terms of the ratio of green (representing JC-1 monomers, and therefore depolarization and lowered MMP) to red (representing JC-1 aggregates) JC-1 fluorescence, were obtained in Vasopressin (AVP) (10 μM; 48 h)-treated cardiomyocytes.

Vasopressin purchased from MedChemExpress. Usage Cited in: Eur J Pharmacol. 2022 Oct 15:933:175262. [Abstract]

Vasopressin (AVP) (10 μM; 48 h) significantly decreased p-Mst1, the active phosphorylated form of Mst1, and nuclear Nrf2 protein levels in cardiomyocytes.
Endocrinology

Aspirin Suppresses Hepatic Glucagon Signaling Through Decreasing Production of Thromboxane A2. [Abstract]

2023 Jan 9;164(3):bqac217. PMID: 36592127
Continence (Amst)

Endogenous vasopressin and vasopressin receptor 2 in bladder as anti-diuretic / anti-spasmodic targets for the treatment of multifactorial nocturia. [Abstract]

2025 Dec:16:102292. PMID: 41503219
SSRN

2026 Jun 16.
SSRN

2023 May 30.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (92.23 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (46.12 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9223 mL

4.6116 mL

9.2231 mL

5 mM

0.1845 mL

0.9223 mL

1.8446 mL

10 mM

0.0922 mL

0.4612 mL

0.9223 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.31 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 25 mg/mL (23.06 mM); Clear solution; Need ultrasonic and warming

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Baribeau DA, et, al. Oxytocin and vasopressin: linking pituitary neuropeptides and their receptors to social neurocircuits. Front Neurosci. 2015 Sep 24;9:335. [Content Brief]

[2]. Ramos L, et, al. Acute prosocial effects of oxytocin and vasopressin when given alone or in combination with 3,4-methylenedioxymethamphetamine in rats: involvement of the V1A receptor. Neuropsychopharmacology. 2013 Oct;38(11):2249-59. [Content Brief]

[3]. Gal CSL, et, al. Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. J Pharmacol Exp Ther. 2002 Mar;300(3):1122-30. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.9223 mL	4.6116 mL	9.2231 mL	23.0578 mL
	5 mM	0.1845 mL	0.9223 mL	1.8446 mL	4.6116 mL
	10 mM	0.0922 mL	0.4612 mL	0.9223 mL	2.3058 mL
	15 mM	0.0615 mL	0.3074 mL	0.6149 mL	1.5372 mL
	20 mM	0.0461 mL	0.2306 mL	0.4612 mL	1.1529 mL
	25 mM	0.0369 mL	0.1845 mL	0.3689 mL	0.9223 mL
	30 mM	0.0307 mL	0.1537 mL	0.3074 mL	0.7686 mL
	40 mM	0.0231 mL	0.1153 mL	0.2306 mL	0.5764 mL
DMSO	50 mM	0.0184 mL	0.0922 mL	0.1845 mL	0.4612 mL
	60 mM	0.0154 mL	0.0769 mL	0.1537 mL	0.3843 mL
	80 mM	0.0115 mL	0.0576 mL	0.1153 mL	0.2882 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Vasopressin

Metabolism/Protease Compound Library

Natural Product Library

FDA-Approved Drug Library

Human Endogenous Metabolite Compound Library

Drug Repurposing Compound Library

Macrocyclic Compound Library

Anti-Cardiovascular Disease Compound Library

FDA Approved & Pharmacopeial Drug Library

Food-Sourced Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Peptide Library

Cyclic Peptide Library

Human Metabolite Library

Off-patent Drug Library

Animal-Sourced Natural Product Library

Bioactive Compound Library Max

Natural Product Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Peptide Compound Library

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Neurotransmitter Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Mass Spectrometry Human Endogenous Metabolite Library

Human Hormone Compound Library

Mass Spectrometry Human Metabolite Library

Natural Product Diversity Scaffold Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Vasopressin

All Endogenous Metabolite Isoforms

Biological Activity

Chemical Information

Publications (7)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Vasopressin Related Classifications

Cat. No.: HY-B1811